Hem › Akut myeloid leukemi › Oregon
Kliniska studier för Akut myeloid leukemi i Oregon
27 studier för Akut myeloid leukemi söker deltagare vid platser i Oregon.
Städer i Oregon
Officiell studietext (engelska)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- och 7 fler
RekryterarObservationsstudieFriska volontärer välkomna
Ålder 40 till 75 · Alla kön · Uppdaterad 2 okt. 2026 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 28 sep. 2026 · NCT05554393A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 25 sep. 2026 · NCT05564390Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT03874052Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 22 sep. 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
RekryterarFas 2
Ålder 18 till 59 · Alla kön · Uppdaterad 22 sep. 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
RekryterarFas 3
6 Months – 21 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT04293562A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
RekryterarFas 1/2
30 Days · Alla kön · Uppdaterad 16 sep. 2026 · NCT04065399Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 16 sep. 2026 · NCT06504459Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
RekryterarFas 1/2
Ålder 18 och äldre · Alla kön · Uppdaterad 14 sep. 2026 · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 2 sep. 2026 · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
RekryterarFas 1/2
Upp till ålder 22 · Alla kön · Uppdaterad 25 aug. 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Doernbecher Children's Hospital, Portland
RekryterarFas 3
29 Days – 21 Years · Alla kön · Uppdaterad 24 aug. 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 20 aug. 2026 · NCT07007312Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
RekryterarFas 3
Ålder 18 till 75 · Alla kön · Uppdaterad 17 juli 2026 · NCT05429632Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 14 juli 2026 · NCT04659616Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RekryterarFas 2
Ålder 18 till 65 · Alla kön · Uppdaterad 13 juli 2026 · NCT07228273Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 7 juli 2026 · NCT07216443Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 6 juli 2026 · NCT07548983A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
RekryterarObservationsstudie
Alla åldrar · Alla kön · Uppdaterad 6 juli 2026 · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 30 juni 2026 · NCT06357182A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 30 apr. 2026 · NCT04256317A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
RekryterarFas 1/2
Ålder 12 och äldre · Alla kön · Uppdaterad 24 mars 2026 · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
RekryterarFas 2
Ålder 18 till 66 · Alla kön · Uppdaterad 17 mars 2026 · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
RekryterarFas 1
Ålder 18 och äldre · Alla kön · Uppdaterad 9 feb. 2026 · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
RekryterarFriska volontärer välkomna
Ålder 18 till 120 · Alla kön · Uppdaterad 25 juli 2025 · NCT05237258Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.